Saturday, July 11, 2026

pharma · Infertility

Reproductive & Genetic

Reproductive & Genetic drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
2
Patents
0
Intelligence · Drug Pipeline

Reproductive & Genetic pipeline

Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Reproductive & Genetic drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

2 compounds
  1. Development asset linked to Reproductive & Genetic in public FDA and regional records. Molecular target: Follicle-stimulating hormone receptor.

    Target
    Follicle-stimulating hormone receptor
    Mechanism
    Follicle stimulating hormone receptor agonist
  2. follitropin beta

    Genito-urinary system and sex hormones (G03)

    Genito-urinary system and sex hormones (G03) compound in Reproductive & Genetic's portfolio. Molecular target: Follicle-stimulating hormone receptor.

    Target
    Follicle-stimulating hormone receptor
    Mechanism
    Follicle stimulating hormone receptor agonist